PHARMACOKINETICS OF INFLIXIMAB (Anti-TNF∞) IN CHILDREN WITH CROHN'S DISEASE: A MULTICENTER TRIAL
Colleen Hadigan(National Institutes of Health), Harland S. Winter(Massachusetts General Hospital), George D. Ferry(Baylor College of Medicine), Barbara S. Kirschner(Comer Children's Hospital), E Vasiliauskis(Children's Hospital of Philadelphia), Kimberly L. DeWoody(Children's Hospital of Philadelphia), Christian Braegger(University Children's Hospital Zurich), Robert B. Livingston(Active Medicine (United Kingdom)), Carrie Wagner(Johnson University), Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital), M. Sinaasappel(Cystic Fibrosis Foundation), Robert N. Baldassano(Children's Hospital of Philadelphia)
Cited by 6
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k